Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

BCS
Home/The Filing Wire/Corbus Pharmaceuticals Holdings, Inc./ 4

Changes in Beneficial Ownership · 4

Corbus Pharmaceuticals Holdings, Inc.

CRBPNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Aug 17, 2026Accepted Aug 17, 2026, 4:30 PM EDTCIK 1595097Accession 0001193125-26-354145
View company →Permanent SEC source ↗
Share

Company context

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Current securities

CRBPNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G - filed by RA CAPITAL MANAGEMENT, L.P. regarding Corbus Pharmaceuticals Holdings, Inc.Sep 30, 2026
  2. Regulation FD Disclosure · Other EventsSep 14, 2026
  3. 4 filingAug 10, 2026
  4. 424B5 filingAug 7, 2026
  5. 144 filingAug 7, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.